Ipca Laboratories Ltd, engaged in manufacturing and marketing of pharmaceuticals, reported robust financial performance for Q2FY26 with revenue growth across domestic formulations, exports, and APIs.
Financial Highlights:
- Revenues increased 8.54% year-on-year to ₹2,556 crore from ₹2,355 crore, with domestic formulations up 8% to ₹1,019 crore and exports up 7% to ₹814 crore.
- Total expenses rose 4.86% to ₹2,135 crore from ₹2,036 crore.
- Consolidated net profit grew 14.23% to ₹281 crore from ₹246 crore, supported by EBITDA margin expansion to 21.68% (up 258 bps).
- Earnings per share improved 23.09% to ₹11.14 from ₹9.05.
Growth driven by API sales surge (28% to ₹408 crore), operational efficiencies, and strong domestic/international demand despite ₹58 crore EU fine provision.
Outlook:
Ipca Laboratories Ltd targets 10-11% domestic growth, consolidated margin improvement, and sustained API/export momentum.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
